LRMR
Price:
$8.05
Market Cap:
$513.64M
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.[Read more]
Industry
Biotechnology
IPO Date
2014-06-19
Stock Exchange
NASDAQ
Ticker
LRMR
According to Larimar Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -7.19. This represents a change of 33.64% compared to the average of -5.38 of the last 4 quarters.
The mean historical PE Ratio of Larimar Therapeutics, Inc. over the last ten years is -4.11. The current -7.19 PE Ratio has changed 17.38% with respect to the historical average. Over the past ten years (40 quarters), LRMR's PE Ratio was at its highest in in the December 2014 quarter at 0. The PE Ratio was at its lowest in in the March 2019 quarter at -5588.18.
Average
-4.11
Median
-2.86
Minimum
-12.34
Maximum
-1.50
Discovering the peaks and valleys of Larimar Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 235.14%
Maximum Annual PE Ratio = -1.50
Minimum Annual Increase = -81.63%
Minimum Annual PE Ratio = -12.34
Year | PE Ratio | Change |
---|---|---|
2023 | -5.41 | 73.70% |
2022 | -3.11 | -15.45% |
2021 | -3.68 | -38.76% |
2020 | -6.01 | 235.14% |
2019 | -1.79 | -31.01% |
2018 | -2.60 | 6.71% |
2017 | -2.44 | 62.42% |
2016 | -1.50 | -33.80% |
2015 | -2.27 | -81.63% |
The current PE Ratio of Larimar Therapeutics, Inc. (LRMR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-4.07
5-year avg
-4.00
10-year avg
-4.11
Larimar Therapeutics, Inc.’s PE Ratio is greater than Vaxcyte, Inc. (-26.31), less than Syndax Pharmaceuticals, Inc. (-6.17), greater than Merus N.V. (-18.45), less than Sutro Biopharma, Inc. (-2.69), less than Immuneering Corporation (-0.62), greater than Centessa Pharmaceuticals plc (-9.93), less than Celcuity Inc. (-7.01), less than Ikena Oncology, Inc. (-1.22), less than Spero Therapeutics, Inc. (4.06), less than Bolt Biotherapeutics, Inc. (-0.37), less than Coherus BioSciences, Inc. (-4.85), greater than Gracell Biotechnologies Inc. (-12.26), less than Neoleukin Therapeutics, Inc. (-0.98), less than Surrozen, Inc. (-0.55), greater than Keros Therapeutics, Inc. (-11.28), less than Kezar Life Sciences, Inc. (-0.41), less than Cabaletta Bio, Inc. (-2.34), less than Homology Medicines, Inc. (-0.01), greater than Day One Biopharmaceuticals, Inc. (-7.39), less than Alector, Inc. (-2.92),
Company | PE Ratio | Market cap |
---|---|---|
-26.31 | $12.45B | |
-6.17 | $1.63B | |
-18.45 | $3.41B | |
-2.69 | $337.69M | |
-0.62 | $34.99M | |
-9.93 | $1.62B | |
-7.01 | $557.67M | |
-1.22 | $81.56M | |
4.06 | $71.07M | |
-0.37 | $24.78M | |
-4.85 | $142.86M | |
-12.26 | $989.87M | |
-0.98 | $8.20M | |
-0.55 | $29.60M | |
-11.28 | $1.97B | |
-0.41 | $40.82M | |
-2.34 | $208.10M | |
-0.01 | $3.02M | |
-7.39 | $1.25B | |
-2.92 | $472.01M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Larimar Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Larimar Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Larimar Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Larimar Therapeutics, Inc. (LRMR)?
What is the highest PE Ratio for Larimar Therapeutics, Inc. (LRMR)?
What is the 3-year average PE Ratio for Larimar Therapeutics, Inc. (LRMR)?
What is the 5-year average PE Ratio for Larimar Therapeutics, Inc. (LRMR)?
How does the current PE Ratio for Larimar Therapeutics, Inc. (LRMR) compare to its historical average?